Close menu




March 5th, 2021 | 10:35 CET

Steinhoff, Upco International, ProSiebenSat.1 - Facing a turnaround?

  • Investments
Photo credits: pixabay.com

Are the stock indices at the turning point? Although the DAX once again reached new all-time highs this week, there was a lack of momentum to confirm them. A correction is already underway in tech stocks. The market for smartphone payments is also on the move. The Corona pandemic has reinforced the movement away from cash to contactless payment methods. The winners are companies that link multiple business areas.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0011375019 , CA9152971052 , DE000PSM7770

Table of contents:


    On the pulse of time

    Absolutely on trend is cloud-based wireless Company Upco International. The Canadians, who shot up the turnaround at the beginning of last year with a change in management and strategy, are focusing strictly on two separate business segments. The Wholesale Division can be equated with traditional telecommunications wholesaling. By pooling smaller customers, better contract terms can be achieved with international telecommunications providers for cross-border telephone traffic. The Wholesale Telecom segment is coordinated by Upco International but managed operationally by dedicated companies that will be integrated into the Upco Group of Companies over time. Here, the aim is to grow inorganically through new acquisitions. Two purchases have already been made in the past year.

    Scaling through linking

    Of course, the wholesale area is also intended to acquire new customers who can then use all the apps of the Upco Group. In this way, users are to be converted into paying customers. Paid services are offered in the second division, Digital Services: Voice and data services, digital payments and money transfers. Voice and data services such as Voice over IP and chats will be handled by UpcoNet, while UpcoPay will handle digital payments.

    Transaction via blockchain

    UpcoPay, which runs on a blockchain-based direct payment method between individuals or people and merchants, is modular and will be highly scaled up before the end of 2021. Thus, it will be possible to load money, process payments, or even transfer foreign exchange without setting up an account or entering sensitive banking information. Later this year, Upco users in Europe should then be able to use UpcoPay to send and receive money easily, securely, and without using a credit or debit card and much more cheaply than competitors such as Western Union or PayPal.

    UpcoPay is set to launch across Europe with Finnish partner Enfuce. After the share performed very well last year, the previous high of EUR 0.30 was reached at the beginning of February. Since then, the stock has been correcting and is looking for its bottom at EUR 0.20. In the long term, the Company's strategy is promising but also fraught with risks.

    Further steps

    Since 2017, retail giant Steinhoff has been dealing with the effects of the accounting scandal. Sales were incorrectly booked, which meant that significant special write-offs were necessary. In addition, incorrect balance sheets had to be corrected retrospectively. If the public prosecutor's office has its way, three top managers will now have to defend themselves before a German court on suspicion of accounting manipulation worth billions. According to the indictment, the charges relate to balance sheet manipulation through fictitious transactions totaling more than EUR 1.5 billion. In addition, real estate is said to have been overvalued by EUR 820 million. The Oldenburg public prosecutor's office brought charges of misrepresentation in balance sheets.

    In total, more than EUR 6 billion are missing from the balance sheet, and the former managers are said to be responsible for the fact that the book profits from the fictitious transactions were included in the balance sheets. Currently, the new management is trying everything to structure the Group, which was worth more than 20 billion at the time. To achieve this, pearls such as "Poco" low-cost furniture stores or the Austrian "Kika" furniture store were sold. An investment in the Steinhoff share is only for hard-core gamblers. All others: Hands off!

    ProSiebenSat.1 - Significant drop in sales

    In contrast to the first quarter, there is expected to be a significant downturn in sales compared with the same period last year. Management anticipates a mid-single-digit percentage decline in revenues. In addition, advertising revenues are expected to shrink by a low double-digit percentage. On the other hand, for the full year, 2 to 7% revenue growth is expected. Advertising revenues are expected to be between minus 2 and 4%. The disappointing outlook caused disgruntlement among investors, with the share price falling by more than 5% in the meantime. Analysts, on the other hand, were divided. While Barclays described the outlook as weak, Goldman Sachs was satisfied. Overall, the targets were below analysts' expectations.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read